US President Trump's administration is readying to impose tariffs of 100% on certain medicines as it pushes pharmaceutical companies to manufacture more in the US, according to FT

The potential imposition of 100% tariffs on certain medicines by the Trump administration signals a significant escalation in trade policy, particularly aimed at reshoring pharmaceutical manufacturing. This move could foster inflationary pressures in the healthcare sector and contribute to volatility in related equities and forex pairs, especially as it may provoke retaliatory measures from trade partners. Market participants should prepare for potential shifts in sentiment across risk assets and safe havens as the situation evolves.